CINECA IRIS Institutional Research Information System

MARMORINO, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.044
EU - Europa 954
AS - Asia 337
AF - Africa 88
SA - Sud America 1
Totale 3.424
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.018
IT - Italia 458
SG - Singapore 152
SE - Svezia 140
CN - Cina 101
BG - Bulgaria 92
DE - Germania 81
GB - Regno Unito 75
CI - Costa d'Avorio 53
VN - Vietnam 40
FR - Francia 31
CA - Canada 26
PL - Polonia 22
NG - Nigeria 19
AT - Austria 16
SN - Senegal 15
IN - India 14
HK - Hong Kong 12
FI - Finlandia 11
RU - Federazione Russa 9
ID - Indonesia 7
NL - Olanda 6
TR - Turchia 5
UA - Ucraina 5
ES - Italia 3
CH - Svizzera 2
CY - Cipro 2
CL - Cile 1
CZ - Repubblica Ceca 1
EE - Estonia 1
EG - Egitto 1
IL - Israele 1
JP - Giappone 1
KR - Corea 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 3.424
Salva come PNG Salva come JPEG
Città #
Woodbridge 294
Fairfield 286
Chandler 196
Ashburn 129
Seattle 122
Ann Arbor 108
Houston 103
Cambridge 102
Wilmington 97
Sofia 92
New York 85
Florence 60
Milan 58
Abidjan 53
Pisa 48
Princeton 47
Lawrence 44
Medford 38
Beijing 31
Serra 31
London 30
Genoa 28
Bremen 25
Singapore 25
Dearborn 23
Ottawa 22
Warsaw 22
Des Moines 21
Lagos 19
Ogden 18
Seacroft 18
Rome 17
Vienna 16
Dakar 15
Lancaster 15
Naples 14
San Diego 14
Nanjing 11
Boulder 10
Dong Ket 10
Hong Kong 10
Turin 10
Los Angeles 8
Redwood City 8
Shanghai 7
Carrara 6
Düsseldorf 6
Marseille 6
Phoenix 6
Kent 5
Kunming 5
Verona 5
Changsha 4
Jakarta 4
Lucca 4
Lusciano 4
Nanchang 4
Pistoia 4
Shenyang 4
Bandung 3
Boardman 3
Frankfurt am Main 3
Guangzhou 3
Hebei 3
Misinto 3
Mumbai 3
Pune 3
San Francisco 3
Washington 3
Adria 2
Anzio 2
Bari 2
Cagliari 2
Campi Bisenzio 2
Capurso 2
Castelvetro di Modena 2
Castrovillari 2
Chengdu 2
Cologno Monzese 2
Council Bluffs 2
Fano 2
Gallarate 2
Hyderabad 2
Jinan 2
Livorno 2
Monza 2
Moscow 2
Nicosia 2
Norwalk 2
Noventa di Piave 2
Padova 2
Peccioli 2
Positano 2
Salerno 2
San Miniato Basso 2
Santa Maria A Monte 2
Sezze 2
Taranto 2
Toronto 2
Vicenza 2
Totale 2.599
Salva come PNG Salva come JPEG
Nome #
TAS-102 for the treatment of metastatic colorectal cancer 131
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 130
null 129
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 111
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 110
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 106
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 106
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 102
Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram 99
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest 95
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 94
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab 93
null 91
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 87
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 86
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 86
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: Challenging drug label to light up new hope 82
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 81
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 80
Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial 78
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer 73
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 73
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis 71
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies 69
Zebrafish Patient-Derived Xenograft Model to Predict Treatment Outcomes of Colorectal Cancer Patients 66
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 64
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO 62
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 62
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients 61
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 59
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials 58
Immune checkpoint inhibitors in pmmr metastatic colorectal cancer: A tough challenge 58
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 57
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 56
Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei 52
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO 48
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies 45
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 44
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 44
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study 41
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies 39
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 39
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 37
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 36
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib 36
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection 29
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 28
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial 26
Surgery combined with intra-operative microwaves ablation for the management of colorectal cancer liver metastasis: A case-matched analysis and evaluation of recurrences 24
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 22
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 21
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 20
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials 19
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study 19
null 15
Fast, Direct Dihydrouracil Quantitation in Human Saliva: Method Development, Validation, and Application 12
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer 11
Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group 6
KDR genetic predictor of toxicities induced by sorafenib and regorafenib 6
Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group 5
Totale 3.590
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.670
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.670
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020623 72 41 24 46 78 82 70 59 59 45 31 16
2020/2021379 15 21 13 14 9 83 33 26 54 25 24 62
2021/2022427 10 11 10 11 65 64 7 19 28 42 35 125
2022/2023763 69 115 45 55 73 90 18 45 148 5 86 14
2023/2024716 49 61 105 65 75 107 66 28 20 27 58 55
2024/20254 4 0 0 0 0 0 0 0 0 0 0 0
Totale 3.590